X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, the compamies aims to develop the first circular RNA-based anticancer drug in South Korea using its next-generation mRNA therapy technology.
Lead Product(s): Circular RNA-based Drug
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: NuclixBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 09, 2023
Details:
EU307 is a fourth-generation CAR-T therapy which targets GPC3-positive solid cancer. It is expected to improve the viability of CAR-T cells and their ability to attack cancer cells through the secretion of cytokine (IL-18).
Lead Product(s): EU307
Therapeutic Area: Oncology Product Name: EU307
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Eutilex Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
Under the agreement, GenScript ProBio will provide GMP plasmid manufacturing service for RVAC Medicines' program, RVM-V001. The partnership will accelerate its clinical manufacturing of future mRNA-based vaccines targeting infectious diseases such as RSV and CDI.
Lead Product(s): RVM-V001
Therapeutic Area: Infections and Infectious Diseases Product Name: RVM-V001
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: RVAC Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 22, 2023
Details:
GenScript ProBio provides IND-enabling CMC service for Bio Immunitas to accelerate the preclinical development of 2 recombinant protein products using Bio Immunitas' proprietary hRPP platform.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Bio Immunitas
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2023
Details:
SLC-3010 selectively stimulates anti-tumor immune response and the efficacy of SLC-3010 in eradication of various types of tumor was thoroughly demonstrated through various in vitro and in vivo experiments.
Lead Product(s): SLC-3010
Therapeutic Area: Oncology Product Name: SLC-3010
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Selecxine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Through this agreement, both companies will strategically cooperate in the overall development process, such as discovery, manufacturing, and clinical trials of antibody and cell treatments, and related research and service projects.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: DAAN Bio Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 14, 2022
Details:
The partnership covers process development and production of viral vectors required for the production of AffyXell’s future cell therapy products. The companies will collaborate in the area of business development, including potential out licensing.
Lead Product(s): Genetically Modified Mesenchymal Stem Cells Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: AffyXell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 16, 2022
Details:
The single-domain antibodies involved in this license agreement will be paired with AskGene's proprietary next-generation cytokine therapeutics for cancer immunotherapy and other applications.
Lead Product(s): Single-domain Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: AskGene Pharma Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 26, 2021
Details:
GenScript ProBio and SYNIMMUNE GmbH entered into collaboration on FLYSYN, a fms-like tyrosine kinase 3 (FLT3) specific antibody for the treatment of acute myeloid leukemia (AML) project for technology transfer and drug product for Clinical Phase II trials.
Lead Product(s): Flysyn
Therapeutic Area: Oncology Product Name: Flysyn
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Synimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 06, 2021
Details:
NX-01 is designed to address the high cost of current coagulation replacement therapy for hemophilia patients.
Lead Product(s): Recombinant Human Coagulation Factor VIII
Therapeutic Area: Genetic Disease Product Name: NX-01
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Neoletix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
